Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients

Clinical Oncology

Volumn 22, Issue 10, 2010, Pages 818-827

  Huyge, V ^a   Garcia, C ^a   Alexiou, J ^a   Ameye, L ^a   Vanderlinden, B ^a   Lemort, M ^a   Bergmann, P ^b   Awada, A ^a   Body, J J ^b   Flamen, P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bone metastases; Heterogeneity of response; Metastatic breast cancer; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; HORMONE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METABOLISM; OUTCOME ASSESSMENT; PLEURA METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT RESPONSE; VISCERAL METASTASIS; WHOLE BODY CT; WHOLE BODY PET;

EID: 78149496663     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.05.021     Document Type: Article

References (24)

1. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12(20 Pt 2):6243s-6249s.
2. Hamaoka T., Madewell J.E., Podoloff D.A., Hortobagyi G.N., Ueno N.T. Bone imaging in metastatic breast cancer. J Clin Oncol 2004, 22:2942-2953.
3. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
4. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
5. Coleman R.E., Mashiter G., Whitaker K.B., Moss D.W., Rubens R.D., Fogelman I. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988, 29(8):1354-1359.
6. Schneider J.A., Divgi C.R., Scott A.M., et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994, 35(11):1748-1752.
7. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
8. Hodgson N.C., Gulenchyn K.Y. Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol 2008, 26:712-720.
9. Dunnwald L.K., Gralow J.R., Ellis G.K., et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008, 26:4449-4457.
10. McDermott G.M., Welch A., Staff R.T., et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007, 102:75-84.
11. Rousseau C., Devillers A., Sagan C., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006, 24:5366-5372.
12. Kim S.J., Kim S.K., Lee E.S., Ro J., Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004, 15:1352-1357.
13. Smith I.C., Welch A.E., Hutcheon A.W., et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000, 18:1676-1688.
14. Stafford S.E., Gralow J.R., Schubert E.K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002, 9(8):913-921.
15. Specht J.M., Tam S.L., Kurland B.F., et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007, 105:87-94.
16. Tateishi U., Gamez C., Dawood S., Yeung H.W., Cristofanilli M., Macapinlac H.A. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008, 247(1):189-196.
17. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47:1059-1066.
18. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
19. Molina R., Barak V., van Dalen A., et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 2005, 26:281-293.
20. Lôrincz T., Tóth J., Badalian G., Tímár J., Szendrôi M. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res 2006, 12(3):149-152.
21. Wu J.M., Fackler M.J., Halushka M.K., et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008, 14(7):1938-1946.
22. Du Y., Cullum I., Illidge T.M., Ell P.J. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007, 25:3440-3447.
23. Mortimer J.E., Dehdashti F., Siegel B.A., Trinkaus K., Katzenellenbogen J.A., Welch M.J. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001, 19(11):2797-2803.
24. Aliaga A., Rousseau J.A., Cadorette J., et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 2007, 9(3):144-150.